Long-term Safety Study of HSK44459 for Behçet's Disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial is for people who have already completed a prior study of the drug HSK44459 for Behçet's disease. It will continue to monitor the safety and effects of the drug over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have completed a previous clinical study of HSK44459 for Behçet's disease.
- No active major organ problems from Behçet's disease (such as in the lungs, blood vessels, stomach, brain, or eyes).
- No serious side effects related to HSK44459 in the prior study.
- No current hepatitis B or C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill, HSK44459, for people with Behçet's disease who have frequent mouth ulcers. It aims to see if the drug can safely reduce ulcer episodes and improve symptoms.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This study looks at how Behçet's disease affects blood clotting. If you have Behçet's disease and are between 18–70, you may help doctors understand why some people with Behçet's develop dangerous blood clots.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
Hear when a new Bechet's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.